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ABSTRACT
Introduction: Patients with diabetes and
prediabetes are at increased risk of
dyslipidemia and cardiovascular disease. To
reduce this risk, statins and additional
therapies may be considered. Omega-3 fatty
acids offer an option to reduce triglycerides
(TG) and potentially improve other lipid
parameters, although products that contain
docosahexaenoic acid (DHA) may increase
low-density lipoprotein cholesterol (LDL-C)
while eicosapentaenoic acid (EPA) does not.
Prescription formulations include omega-3-acid
mixtures (combination of predominantly EPA
and DHA), and icosapent ethyl (high-purity
prescription form of EPA ethyl ester);
prescription omega-3 products are indicated as
an adjunct to diet to reduce TGs in adult
patients with severe hypertriglyceridemia at a
dose of 4 g/day.
Methods: This was a retrospective analysis of
records from a private endocrinology practice of
patients who received omega-3-acid ethyl esters
(OM3EE) (4 g/day) and were subsequently
switched to icosapent ethyl (IPE; 4 g/day) due
to the potential of OM3EE to raise LDL-C and/or
cause gastrointestinal upset. Patient records
were analyzed for LDL-C, TG, total cholesterol
(TC), high-density lipoprotein cholesterol
(HDL-C), and non-HDL-C measured before and
after the switch to IPE.
Results: The records of ten patients met the
criteria for this analysis and were included. All
patients had taken OM3EE for C1 year prior to
their last lipid measurement before switching to
IPE, and all had been taking IPE for[3 months
at the time of their subsequent lipid
measurement. Nine of the ten patients were
on concomitant statin therapy throughout.
Reductions in LDL-C, TC, and non-HDL-C
were observed in eight patients, reductions or
no changes in TG were observed in eight
patients, and increases or no changes in
HDL-C were observed in eight patients. No
gastrointestinal adverse events were observed.
Conclusion: In most patients with prediabetes
or diabetes who switched from OM3EE to IPE,
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LDL-C and other lipid parameters improved. IPE
was well tolerated.
Keywords: Diabetes; Docosahexaenoic acid;
Dyslipidemia; Eicosapentaenoic acid; Icosapent
ethyl; Lovaza; Low-density lipoprotein
cholesterol; Triglycerides; Vascepa
INTRODUCTION
Dyslipidemia is common in patients with
diabetes and prediabetes and is a risk factor for
cardiovascular disease (CVD) [1]. Medical
guidelines from the American Diabetes
Association (ADA) and the American
Association of Clinical Endocrinologists
(AACE) recommend statins for the
pharmacologic management of dyslipidemia
in patients with diabetes or prediabetes [1, 2].
Despite the beneficial effects of statins on
low-density lipoprotein cholesterol (LDL-C),
some patients may have a residual risk of
cardiovascular (CV) events, CV death, and
myocardial infarction due to the effects of
elevated triglycerides (TGs) [3, 4], as statins
achieve only a 10–30% reduction in TGs [5].
The Residual Risk Reduction Initiative defines
residual CV risk as the risk of CV events that
persists despite achievement of LDL-C, blood
pressure, and glycemic treatment goals [6].
Thus, add-on therapy may be needed to
control TGs and TG-rich lipoproteins and to
further reduce risk in some statin-treated
patients. Such adjunct therapies include
omega-3 fatty acids (OM3FAs) [2].
The OM3FAs eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) have numerous
known CV benefits in patients with dyslipidemia
such as antidysrhythmic, antiatherogenic,
antiinflammatory, antithrombotic, and
antihypertensive effects, and in particular,
reduction of TGs [7, 8]. OM3FA therapies are
approved by the United States Food and Drug
Administration for use as adjunct to diet to
reduce TGs in adult patients with severe
(C500 mg/dL) hypertriglyceridemia. Approved
formulations commercially available at the
time of this analysis were omega-3-acid ethyl
esters (OM3EE; Lovaza; GlaxoSmithKline,
Research Triangle Park, North Carolina, USA), a
formulation that contains a combination of the
ethyl esters of EPA and DHA [9], and icosapent
ethyl (IPE; Vascepa; Amarin Pharma Inc.,
Bedminster, New Jersey, USA), a high-purity
prescription form of EPA ethyl ester [10]. Each is
administered as a daily dose of 4 g. Notably,
OM3FA formulations that contain DHA have
been associated with increases in LDL-C, but EPA
does not increase LDL-C [11]. Similarly, the
prescribing information of OM3EE warns that
increases in LDL-C have occurred in some
patients and recommends periodic LDL-C
monitoring [9], while the prescribing
information of IPE does not contain this
warning.
Based on the known beneficial effects of
OM3FAs, and in an effort to reduce TG and/or
CV risk in patients in our private endocrinology
practice, we began prescribing OM3EE to
patients based on our overall assessments of
their clinical status and potential for CV risk. In
addition to the known possible increase in LDL-
C associated with OM3EE use and consistent
with the Adverse Reactions section of the
OM3EE prescribing information [9], we noted
that gastrointestinal problems and fishy
eructation [12] were among the side effects
that interfered with compliance in our practice.
When IPE became commercially available in
2013, we noted that it contained purified EPA,
which could reduce TG without the increases in
LDL-C associated with OM3EE, and that the
incidence of eructation and gastrointestinal
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upset in statin-treated patients was lower than
that seen in statin-treated patients receiving
placebo [10, 13, 14]. In our clinical judgment,
IPE had the potential for fewer side effects and
to be better tolerated, with no adverse effects on
LDL-C, so we began switching our patients from
OM3EE to IPE. The objective of the current
analysis was to retrospectively assess the lipid
profiles of adult patients with diabetes or
prediabetes who had been receiving OM3EE
and were subsequently switched to IPE.
METHODS
Study Design
This was a retrospective chart review of patients
in a private endocrinology practice in Houston,
Texas. Records for diabetic and prediabetic
patients who had been receiving OM3EE and
subsequently underwent a switch to IPE were
identified through a search of Electronic
Clinical Works (ECW)/Electronic Health
Records (EHR). The authors received approval
from the Western Institutional Review Board,
Puyallup, WA, for the conduct of this study.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
Patients and Treatment
Patients were eligible if they had well-controlled
diabetes or prediabetes and hyperlipidemia; had
been switched from OM3EE 4 g/day to IPE 4 g/
day; had been taking IPE for more than
2 months; had available lipid measurements;
and had been clinically stable over the course of
the period examined. Patients were excluded if
they had poor thyroid function, uncontrolled
diabetes, insulin use, gaps in treatment, missing
laboratory values, known noncompliance,
changes in lipid-lowering medications, or were
taking niacin, fibrates, bile acid sequestrants, or
other OM3FA products (including dietary
supplements). Use of ezetimibe was permitted.
Assessments
Fasting blood samples were collected from
patients and analyzed at local branches of large,
national clinical laboratories (either Quest
Diagnostics or LabCorp) according to patient
insurance coverage. Lipid measurements
[LDL-C, TG, total cholesterol (TC), high-density
lipoprotein cholesterol (HDL-C), and
non-HDL-C] were analyzed at dates prior to
initiation of OM3EE, at the latest date with
available data prior to switching from OM3EE to
IPE, and at least 2 months after the switch from
OM3EE to IPE. Percent changes were calculated
frommeasurements at latest date available while
on OM3EE to measurements made while on IPE.
LDL-C assessments were calculated by the
clinical laboratory. Non-HDL-C was calculated
as TC minus HDL-C [15]. Lipid values for
individual patients while on OM3EE and after




Of the patient records retrieved from the ECW/
EHR database, ten met the inclusion criteria and
were analyzed. The population included eight
adult males and two adult females ranging in
age from 42 to 66 years (Table 1) who initiated
OM3EE treatment between June 2007 and
August 2012 and switched to IPE treatment
between January and June 2013. Nine of the ten
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patients were receiving a statin (rosuvastatin,
atorvastatin, or simvastatin); one statin-treated
patient was also receiving ezetimibe (Table 1).
Other medications are listed in Table 2; no
changes in medications that would affect
cholesterol or TGs occurred during the course
of treatment with OM3EE or IPE. All patients
had been taking OM3EE for C1 year (range
1.0–5.6 years) prior to measurement of lipid
levels while on OM3EE and all had been taking
IPE for[3 months (range 3.9–8.4 months) prior
to measurement of lipid levels while on IPE. The
time elapsed between the measurements taken
while on OM3EE and while on IPE ranged from
4.0 to 25.7 months.
Diabetes had been diagnosed in eight
patients, one of the remaining patients had
elevated fasting plasma glucose, and the other
was noted as having elevated blood sugar
(Table 1). Eight patients also had hypertension
(Table 1).
Following the switch from OM3EE to IPE, no
gastrointestinal adverse events or fishy odor/
eructation were reported. IPE was well tolerated.
Effects on Lipid Parameters
Percentage changes in lipid values after the
switch from OM3EE to IPE are shown in
Table 1. Lipid levels for patients while on
OM3EE before the switch to IPE ranged from
53 to 168 mg/dL for LDL-C, 65 to 278 mg/dL for
TG, 66 to 210 mg/dL for non-HDL-C, 108 to
255 mg/dL for TC, and 37 to 68 mg/dL for
HDL-C. Lipid levels for patients while on IPE
ranged from 55 to 122 mg/dL for LDL-C, 71
to 213 mg/dL for TG, 71 to 159 mg/dL for
non-HDL-C, 110 to 228 mg/dL for TC, and 37
to 86 mg/dL for HDL-C.
Figure 1 summarizes the individual lipid
levels before and after the switch from OM3EE




































































































































































































































































































































































































































































































Cardiol Ther (2015) 4:83–93 87
were observed in eight patients, reductions or
no changes in TG were observed in eight
patients, and increases or no changes in HDL-C
were observed in eight patients.
DISCUSSION
In this retrospective analysis of patients with
diabetes or prediabetes, we sought to evaluate
the lipid profiles in patients switched from
OM3EE to IPE in our private clinical
endocrinology practice. We found that, in
most cases, patients experienced decreases in
LDL-C, TG, non-HDL-C, and TC and increases
in HDL-C following the switch to IPE. Two
patients (numbers 4 and 6) experienced
increases in LDL-C, TG, non-HDL-C, and TC
after switching to IPE, although lipid levels in
patient 4 were still within the acceptable
range as specified by the AACE [2] and
the recent National Lipid Association
(NLA) recommendations for patient-centered
management of dyslipidemia [16]. In patient
6, the increase in LDL-C was relatively small
(from 113 to 116 mg/dL), and TGs were still
within the acceptable range as specified by the
AACE and NLA. Overall, the effects seen
represented improvements in the assessed lipid
parameters in most patients.
Our findings are similar to those of other
recent reports of patients switched from
EPA ? DHA formulations to IPE. Case studies
of two patients with type 2 diabetes and
dyslipidemia who were switched from either a
dietary supplement containing EPA ? DHA or
OM3EE to IPE showed improvements in LDL-C,
TG, non-HDL-C, and nominal effects on HDL-C
[17]. In addition, in a retrospective case series of
14 statin-treated patients with hyperlipidemia
from a private practice in 4 Western New York
locations, switching from OM3EE to IPE
achieved reductions in LDL-C, TGs, non-HDL-C,
and TC in most cases [18]. There were three
patients in the Western New York study that
had diabetes, and all three experienced
reductions in non-HDL-C and TC following
the switch from OM3EE to IPE. Two of the
three patients with diabetes experienced TG
reductions; one patient experienced an increase
in TG from 62 to 81 mg/dL, which may not be
considered clinically significant, as 81 mg/dL is
considered to be within the acceptable range as
specified by the guidelines of the NLA [16],
AACE [2], and the Endocrine Society [19]. Two
of these three patients also experienced
reductions in LDL-C, while one patient had a
reported LDL-C increase of 39.8%. However,
upon calculating the expected LDL-C level in
this patient based upon the Friedewald formula
(LDL-C = TC minus HDL-C minus TG/5; all
values given in mg/dL) [20], the LDL-C level in
this patient while on OM3EE would be
expected to have been 173 mg/dL and not
123 mg/dL as reported, resulting in an actual
0.6% decrease in LDL-C following the switch
from OM3EE to IPE.
Table 2 Other medications
Antidiabetics Exenatide, glimepiride, glipizide, liraglutide, metformin, pioglitazone, saxagliptin, sitagliptin
Antihypertensives Bisoprolol, clonidine, irbesartan, lisinopril, losartan, metoprolol, olmesartan
Dietary supplements Folic acid, glucosamine, vitamin B12, vitamin D (with or without calcium)
Others Adefovir, aspirin, celecoxib, duloxetine, levothyroxine, loratadine, testosterone gel, vardenaﬁl
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The results of our retrospective analysis are
consistentwiththe resultsofclinical trialsof IPE for
both efficacy and tolerability. The phase 3,
multicenter, placebo-controlled, randomized,
double-blind, 12-week ANCHOR (NCT01047501)
study examined the safety and efficacy of IPE in
high-risk statin-treated patients with residually
high TGs (C200 and\500mg/dL) despite statin
control of LDL-C (C40 and B115 mg/dL). In a
subanalysis of patients with diabetes from the
ANCHOR study, IPE 4 g/day significantly
decreased median LDL-C by 6.3% (P= 0.02), TGs
Fig. 1 Individual lipid parameters before and after the
switch from omega-3-acid ethyl esters (OM3EE) to
icosapent ethyl (IPE) in patients with diabetes/prediabetes.
a Low-density lipoprotein cholesterol (LDL-C);
b triglycerides (TG); c non-high-density lipoprotein cho-
lesterol (non-HDL-C); d total cholesterol (TC); and
e high-density lipoprotein cholesterol (HDL-C)
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by 23.2% (P\0.0001), non-HDL-C by 14.4%
(P\0.0001), TC by 12.7% (P\0.0001), and
HDL-C by 5.0% (P\0.01) compared with
placebo [21]. The decreases in LDL-C, TG,
non-HDL-C, and TC in the present analysis are
consistent with these results, with perhaps
somewhat more robust reductions in LDL-C
observed in our analysis. However, the increases
in HDL-C in our analysis differ somewhat from
the small but significant decreases in HDL-C in
the ANCHOR subanalysis. It is unclear why this
difference was observed, but may perhaps be
attributable to differences in the patient
populations, differences in concurrent
medications, and/or other unknown factors.
Similar to results of clinical trials where
tolerability of IPE was comparable to placebo
[13, 14], IPE was well tolerated in our patient
population, with no gastrointestinal adverse
events reported.
Our findings are novel in that we examined
the effects of switching from OM3EE to IPE in
patients with diabetes or prediabetes, an
important patient population with respect to
CVD risk. While patients in this analysis may
not have been receiving a maximally approved
statin dose, each patient was receiving their
own maximally tolerated dose. Our experience
has been that patients may have difficulty
tolerating higher statin doses due to adverse
effects such as muscle aches and fatigue.
Diabetes in these patients was well controlled
as were TGs in most cases.
It is our opinion that the unmet need of
residual CV risk in our patients should be
addressed, and thus we prescribe prescription
OM3FA products in our endocrinology practice.
The results of this analysis support switching
such patients from OM3EE to IPE, including
those receiving statin treatment. The TG-
lowering effects of OM3FAs are well
established [22] and reducing very high TG is
a well-accepted treatment approach to reduce
the risk of pancreatitis [16]. However, results of
OM3FA outcomes studies have been
inconsistent or somewhat controversial [23–
32]. Disappointing results wherein lack of
effect of OM3FAs on CV outcomes was
observed may have been due in part to
intervention with low doses of OM3FA
(*1–2 g/day) in the context of background
contemporary statin therapy [26, 27, 32].
Other factors may include differences in
baseline CV risk, baseline TGs, and
background dietary OM3FA intake. However,
the results of the Japan EPA Lipid Intervention
Study (JELIS) support long-term use of highly
purified EPA with concomitant statin therapy
for the primary and the secondary prevention of
major coronary events [28, 29, 33]. In
particular, a subgroup analysis of primary
prevention in patients from JELIS
demonstrated that the risk for major coronary
events was particularly high in patients with
high TGs and low HDL-C and that EPA potently
suppressed major coronary events in these
patients [29]. Furthermore, recent genetic
studies of apolipoprotein C3 have suggested a
causal role for TG-rich lipoproteins in the
development of CVD [34, 35]. Thus, the role
for OM3FAs in the prevention of CV events
bears further investigation. The effects of IPE on
CV outcomes are currently being evaluated in
the ongoing Reduction of Cardiovascular
Events with EPA–Intervention Trial (REDUCE-
IT; NCT01492361), a phase 3, randomized,
parallel-assignment, double-blind safety and
efficacy study [36]. In REDUCE-IT, patients are
receiving IPE 4 g/day or placebo and have
persistent hypertriglyceridemia despite statin
treatment along with established CVD or high
risk for CVD. The purpose of the trial is to
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investigate whether preventative therapy with
IPE ? statin is superior to statin therapy alone in
the long-term reduction of CV events. The
results of this trial are highly anticipated and
should provide key insights into the role of TG-
lowering therapy in the reduction of CV risk
and events. It will be the first trial of its kind to
examine the effects of OM3FAs on CV outcomes
in patients with persistently high TG.
The current analysis was exploratory and
may be of interest to the clinical community for
potential future prospective studies. The
limitations of the current analysis are that it
was conducted retrospectively with a small
number of patients at a single endocrine clinic
and that the same time points and clinical
laboratory were not used for all lipid
assessments. Other real-world limitations
include lack of verification that lipids were
measured in the fasted state and heterogeneity
with regard to concomitant medications other
than OM3EE and IPE and underlying medical
conditions other than diabetes. Given the small
sample size and patient heterogeneity, data
were summarized descriptively. Further
prospective and/or retrospective investigation
would be helpful to better understand the
effects of switching from OM3EE to IPE in
patients with diabetes or prediabetes.
CONCLUSIONS
In this analysis of patients with prediabetes or
diabetes in a private endocrinology clinical
practice who were switched from OM3EE to
IPE, LDL-C, TG, non-HDL-C, TC, and HDL-C
improved in most patients. IPE was well
tolerated after switching from OM3EE. Taken
together, the evidence to date suggests that
treatment with IPE produces beneficial effects in
patients with diabetes who may also be
receiving statin therapy, and that switching
patients from OM3EE to IPE offers a therapeutic
option that results in a beneficial lipid profile.
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